04-Mar-2026
Download PDF
Glenmark Pharmaceuticals
Glenmark Specialty SA Receives U.S. FDA approval for Fluticasone Propionate Inhalation Aerosol USP 44 mcg per actuation with 180-Day Competitive Generic Therapy Exclusivity
Disclaimer: This content is for information only and should not be considered investment advice or a recommendation.
For grievances: [email protected]
Ask Value Research 
Widely read:
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
